Shoulder Innovations Inc Dossier - Source-backed chat

Shoulder Innovations Inc

SINYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.52

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $18.75Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $390.4M

Enterprise Value $393.8M

Shares Outstanding 20.7M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Shoulder Innovations, Inc. (NYSE: SI) is a high-growth, commercial-stage medical technology company exclusively focused on the shoulder arthroplasty market. The company's proprietary InSet™ Glenoid technology directly addresses glenoid loosening—the primary cause of shoulder replacement failures. Backed by robust clinical data, a highly efficient 'Power of One' single-tray instrumentation system, and an expanding product portfolio (including the newly launched InSet I-135RFX Humeral Stem), Shoulder Innovations is rapidly capturing market share from legacy orthopedic giants. Despite near-term net losses driven by aggressive commercial expansion and R&D investments, the company's stellar gross margins (~77-78%) and strong balance sheet ($108.5M in cash) position it well for long-term profitability and make it an attractive acquisition target in a consolidating medtech sector.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$26.25

High · most bullish analyst$28.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$19.0020%

Commercial expansion slows due to intense competitive responses from larger, diversified orthopedic competitors (e.g., Stryker, Zimmer Biomet). Surgeon onboarding bottlenecks, and the adoption of the InSet I-135RFX Humeral Stem falls short of expectations. High SG&A expenses and elevated R&D cash burn persist, accelerating the need for dilutive capital raises before the company achieves self-sustaining cash flows, depressing the valuation multiple.

Base CaseCentral scenario

$21.6750%

Shoulder Innovations successfully executes its commercial strategy, meeting its raised FY 2026 net revenue guidance of $65 million to $68 million (representing 37% to 44% YoY growth). The company continues to expand its core and contender surgeon base and maintains stable gross margins of approximately 77%. While operating losses persist due to ongoing investments in the sales force and robotic platform development, the company's cash runway remains robust, supporting a steady upward re-rating of the stock toward consensus targets.

Bull CaseUpside scenario

$24.0030%

Accelerated surgeon adoption and rapid commercial scaling of the InSet I-135RFX Humeral Stem drive 2026 revenues above the high end of guidance to $72 million. Deeper penetration of the high-volume U.S. shoulder specialist market, combined with successful integration of the INS micro-robotic platform, establishes SI as the premier technology leader in shoulder arthroplasty. Operating leverage kicks in faster than expected, narrowing net losses significantly and attracting a premium buyout offer from a major orthopedic player.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated, clinically proven InSet™ Glenoid technology addressing the leading cause of shoulder implant failure.
Exceptional top-line momentum with 65% YoY revenue growth in Q1 2026 and a raised full-year outlook.
Industry-leading gross margins of ~77.7%, demonstrating strong underlying product economics.
Highly efficient 'Power of One' single-tray system that reduces operating room time and sterilization costs for hospitals.
Strong liquidity position with $108.5 million in cash and marketable securities as of March 31, 2026.

Key Investment Risks

Ongoing operating losses and high cash burn rate as the company invests heavily in commercial infrastructure.
Product concentration risk, with performance heavily tied to the shoulder arthroplasty market.
Intense competition from well-capitalized, multi-line orthopedic giants with established hospital contracts.
Execution risks associated with the development and commercialization of the new micro-robotic platform.

Thesis Invalidation Triggers

A sharp deceleration in year-over-year revenue growth below 25%.
Significant deterioration of gross margins below 72% due to pricing pressure or supply chain inefficiencies.
Unexpected regulatory delays or technical failures in the development of the INS robotic platform.
Rapid depletion of cash reserves requiring highly dilutive equity financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.